The 5th Lipid Nanoparticles Development Summit Europe returns to Berlin, 23rd – 24th  September 2026, as the leading meeting for advancing LNP-enabled gene therapy delivery. Bringing together experts from BioNTech, AstraZeneca, Johnson & Johnson, Sanofi and AbbVie, the summit covers end-to-end LNP development, from formulation through to analytics, CMC and scalable manufacturing. Attendees will explore solutions to overcome liver tropism, enable extrahepatic delivery and engineer next-generation nanoparticle […]

The FDA has shown its' hand. The Plausible Mechanism Framework and new NGS safety guidance signal one thing clearly: regulators want genome editing therapies to reach patients. Biopharma is also pushing back with a surge of novel genome editing assets deployed in the last 2 years, targeting rare and prevalent diseases with scarce treatment options. […]

10th Anniversary Edition of the IPF Summit - September 29 – October 1, 2026 | Boston, MA For a decade, the IPF Summit has been the go-to, discussion-led forum uniting stakeholders across the pulmonary fibrosis ecosystem. In its 10th anniversary year, the stakes, and the opportunity, have never been higher. Following a wave of positive […]

AI is no longer a future concept in life sciences – it is actively reshaping how work gets done, how decisions are made, and how value is created. Yet most organisations are still navigating how to move from ambition to enterprise-wide execution. The Designing the AI-Enabled Life Sciences Workforce Summit Europe is the only forum built […]

The mRNA Process Development & CMC Summit returns for its 5th Anniversary, bringing together the brightest minds in mRNA development, manufacturing, and CMC strategy. As the field continues to evolve at pace, this milestone edition is your opportunity to connect, learn, and stay ahead of the curve with the leaders shaping the future of mRNA […]

Fueled by surging digital pathology partnerships, improved MRD sensitivity and high-plex single‑cell and multi‑omic profiling to breakthroughs, the precision medicine field is evolving rapidly. Building on this momentum, the 16th World Clinical Biomarkers & Companion Diagnostics Summit returns to Boston this fall, uniting 850+ senior stakeholders in the common goal of advancing timely, accessible and […]

Returning as the largest and definitive ADC congress, the 17th World ADC San Diego is THE one-stop bioconjugate shop, bringing together the global ADC community for an unparalleled amalgamation of case studies, development trends and networking opportunities to forge ADC innovation into differentiated, early-line patient outcomes. With 7 streams of end-to-end ADC content across Discovery […]

Early Access Programmes have evolved into a critical, but increasingly complex, part of drug development and launch strategy. What was once a reactive pathway is now a strategic lever shaping timelines, evidence generation, and patient access across global markets. The 5th Operationalise: Early Access Programmes Summit Europe is built for the teams responsible for turning […]

4th Covalent Drug Discovery & Development Summit (October 20–22, Boston, MA) Covalent drug discovery is entering a defining era. Once constrained by safety and selectivity concerns, advances in chemistry, screening technologies, and translational science are unlocking covalent approaches as a powerful strategy to target previously inaccessible biology. As the field evolves, the challenge is no […]

After a decade of innovation, the TPD field has its first drug approval in the form of Arvinas’ Veppanu. Combined with the recovering market of 2026, this clinical validation will unleash a new wave of innovative approaches and push TPD to a new inflection point. Already, the headwinds are reversing with $15B worth of upfront […]

Cell and gene therapies are advancing into late-stage development and commercialization, where raw materials have become a critical determinant of whether programs succeed or fail. Small inconsistencies that once went unnoticed are now triggering regulatory scrutiny, inflating cost of goods, and causing delays that put timelines and patient access at risk. Following the sunshine to […]

The 14th IMPACCT Real-World Evidence Summit is the only dedicated industry forum uniting leaders across RWE, real-world data, evidence generation, HEOR, and market access to tackle the most pressing challenges in the field. From selecting regulatory-ready datasets to embedding AI and advanced analytics into workflows, this summit focuses on how to consistently translate data into […]

GLP-1s changed the treatment paradigm for obesity reaching new heights of efficacy. Now, as unmet need persists and the field looks beyond efficacy alone, momentum is building behind therapies that can deliver lasting weight management through improved tolerability, muscle preservation, personalised treatment approaches, and more convenient administration. As obesity investment and pipeline activity surge across […]

10th Dermatology Drug Development Summit – Discovering, Developing & Commercializing Next-Generation Inflammatory Skin Disease Therapeutics - November 3-5, 2026 | Boston, MA The 10th Dermatology Drug Development Summit returns in 2026 as the leading premier forum dedicated to advancing the discovery, development, and commercialization of innovative therapies for inflammatory skin disease. Marking a decade of […]

3rd ADC Payload Summit | November 4-6, 2026 | Boston, USA The 3rd ADC Payload Summit is the premier industry event dedicated exclusively to advancing payload innovation within the antibody-drug conjugate (ADC) landscape. Bringing together leading experts from across payload discovery, medicinal chemistry, biology, translational science, toxicology, and ADC development, the summit provides a focused […]

Translating Advanced Microbiome Science into Clinical & Commercial Impact, to Build Investor Confidence and Deliver Safe, Effective Solutions for End Consumers. Momentum is returning to microbiome-based therapies. Companies like Vedanta Biosciences, Siolta Therapeutics, Microbiotica and Seres Therapeutics are moving closer to commercialisation across C. diff, oncology and immune-related diseases. Recent financings, including mbiomics (€30M), Kanvas […]

The 9th RNA-Targeted Drug Discovery & Development Summit returns to Boston, MA, on November 10–12, 2026, as the industry's only dedicated meeting focused exclusively on RNA-targeted small molecules, bringing together leading minds from biotech, pharma and academia to advance the next generation of RNA-focused therapeutics. As momentum continues to build across the field, driven by recent clinical progress and […]

The 9th Lab Asset & Facility Management (LAFM) Summit 2026 is the leading industry forum dedicated to helping pharmaceutical and biotech organizations optimize lab operations, asset management, facilities, engineering, and research infrastructure. Taking place in Boston, MA from November 10–12, 2026, the flagship event brings together 190+ senior leaders and decision-makers responsible for creating efficient, […]

Driven by South Korea’s government making strategic investments in mRNA platforms and growing collaboration between global pharma and local biotech innovators, the field is experiencing renewed development momentum. This is placing the region as a key hotspot for global mRNA innovation and interest. Uniquely positioned as the industry’s most comprehensive biopharma forum, the 2nd World RNA-Based […]

Hot off the press: The biomarker operations and biospecimen community finally has its own dedicated forum. Introducing the inaugural Biomarker Operations & Biospecimen Management Summit, the industry's first, purpose-built meeting for the heads, VPs and leading stakeholders at pharma and biotech directly responsible for biospecimen and biomarker delivery. View the newly released agenda:  https://ter.li/p9sor70u With […]

As model-informed drug development (MIDD) becomes increasingly central to modern drug development strategy, organizations are under growing pressure to leverage quantitative approaches that accelerate timelines, reduce risk, and improve regulatory and clinical success. The 2nd Model-Informed Drug Development Summit, taking place November 17-19, 2026, in Boston, MA, brings together senior leaders in pharmacometrics, clinical pharmacology, […]

Introducing Europe’s first CNS Biomarker Forum. The Novel CNS Biomarkers Summit Europe is the only European meeting dedicated exclusively to advancing fluid, imaging, and digital biomarkers for CNS drug development. Bringing together biomarker, translational medicine, neuroscience, and clinical development leaders, the summit focuses on accelerating the discovery, validation, and implementation of next-generation biomarkers across neurodegenerative and […]

The 8th CNS Drug Delivery Summit is the leading industry forum dedicated to overcoming the challenges of delivering therapeutics across the blood-brain barrier and into the central nervous system. Bringing together experts from biopharma, biotech, and academia, the summit will explore the latest advances in drug delivery technologies, including nanoparticles, antibody shuttles, gene therapy vectors, […]

The 4th Cell Therapy for Autoimmune Disease Summit is the premier industry forum uniting biopharma leaders, clinical innovators, and scientific pioneers dedicated to advancing the next generation of cell therapies for autoimmune diseases. As the field progresses beyond early proof-of-concept studies and begins to generate increasingly robust clinical data, organizations are shifting their focus toward […]

Antifibrotic Drug Development Summit 2026 | December 1-3, 2026 | Boston, MA, USA The 10th Antifibrotic Drug Development Summit is the industry's only dedicated forum focused on cross-indication antifibrotic drug development, bringing together 60+ senior leaders across discovery, preclinical, translational, biomarker, and early clinical development. This landmark anniversary meeting will explore how shared fibrosis biology, […]

Amylin‑Based Therapeutics Summit | December 1-3, 2026 | Boston, MA The amylin analog space is rapidly expanding in 2026, with new companies entering the field, stealth programs beginning to emerge, and major investment from Roche–Zealand Pharma and AbbVie–Gubra reinforcing growing confidence in the modality. With biology still being unlocked and multiple development paths on the table, there remains headroom to define best‑in‑class amylin […]

The World CNS Summit South Korea is the premier industry-focused forum dedicated to advancing targeted, mechanism-differentiated therapies for neurodegenerative, rare neurodevelopmental, and neuropsychiatric disorders. As South Korea emerges as a major center for neuroscience innovation, the summit convenes biopharma leaders, translational scientists, and drug developers to explore the next generation of CNS therapeutics and accelerate […]

The 10th Complement-Based Drug Development Summit returns at a pivotal moment as the field shifts from validating complement biology to maximizing its clinical and commercial potential. As pipelines expand beyond C3 and C5 and competition intensifies, developers are focused on identifying the right targets, modalities, and indications to drive differentiation and patient impact. Recent milestones, including Regeneron's cemdisiran advancing […]

Optimizing Tolerability, Quality of Weight Loss & Personalized Therapies to Drive Competitive Drug Development As obesity drug development enters a defining new chapter, the race is no longer about developing the next GLP-1, but delivering the next breakthrough in tolerability, muscle preservation, patient adherence, precision medicine, and long-term outcomes. With hundreds of obesity assets in […]

The 5th Ophthalmic Drug Delivery Summit is where the innovators behind the next generation of ocular therapies come together to solve one critical challenge: getting the right therapy to the right place in the eye. Hear directly from leaders at Kodiak Sciences, Re-Vana Therapeutics, Ripple Therapeutics, Eli Lilly, Genentech, Sanofi, Astellas, Apellis, Beacon Therapeutics, Kriya […]